Trial Profile
Evaluation of 9-cis retinoic acid (9-CRA, NSC#659722) [alitretinoin] in the treatment of recurrent or persistent endometrial carcinoma previously treated by chemotherapy
Status:
Active, no longer recruiting
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 01 Dec 2005
Price :
$35
*
At a glance
- Drugs Alitretinoin (Primary)
- Indications Endometrial cancer
- Focus Therapeutic Use
- 01 Dec 2005 New trial record.